Search Results - "Chooback, N"

  • Showing 1 - 6 results of 6
Refine Results
  1. 1

    ALK inhibitors, resistance development, clinical trials by Rothenstein, J M, Chooback, N

    Published in Current oncology (Toronto) (01-06-2018)
    “…The treatment of advanced non-small-cell lung cancer (nsclc) has undergone a paradigm shift since the early 2000s. The identification of molecular subtypes of…”
    Get full text
    Journal Article
  2. 2

    Carcinoma ex pleomorphic adenoma: case report and options for systemic therapy by Chooback, N, Shen, Y, Jones, M, Kasaian, K, Martin, M, Ng, T, Thomson, T, Marra, M, Laskin, J, Ho, C

    Published in Current oncology (Toronto) (01-06-2017)
    “…The most common benign salivary tumour is a pleomorphic adenoma. Transformation to malignancy, carcinoma ex pleomorphic adenoma (cxpa), occurs in 6% of cases…”
    Get full text
    Journal Article
  3. 3
  4. 4

    Outcome Differences Between First- and Second-generation EGFR Inhibitors in Advanced EGFR Mutated NSCLC in a Large Population-based Cohort by Lau, Sally C., Chooback, Negar, Ho, Cheryl, Melosky, Barbara

    Published in Clinical lung cancer (01-09-2019)
    “…Second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) appear superior to first-generation TKIs in clinical trials, but at…”
    Get full text
    Journal Article
  5. 5

    Canadian Lung Cancer Conference 2017 by Chooback, N., Melosky, B., Ho, C.

    Published in Current oncology (Toronto) (01-08-2017)
    “…The 2017 Canadian Lung Cancer Conference was held 9–10 February in Vancouver, British Columbia. Each year at this prestigious event, hundreds of professionals…”
    Get full text
    Journal Article
  6. 6